James Thompson

A medical device company that manufactures The TayCo Brace, a custom fit external ankle brace. The TayCo Brace offers immediate functional recovery for driving, work, and sports. It is custom fit for enhanced stability, performance, and comfort. The brace was developed by Mike Bean, the athletic trainer for the University of Notre Dame Football Team. It is rugged enough to withstand the punishment of a NFL or NCAA football game, yet light weight and nimble enough to reduced the risks of additional injuries through the elimination of limb imbalance and avoidance of soft tissue problems associated with casts, walking boots, and AFOs.

Our mission is to provide an easy weight management solution with no negative side effects while building a great team and providing shareholder value. We place focus on being thorough, trustworthy, and data driven. We value fun and are committed to learning and sharing our knowledge. We promise not to sell a product that we wouldn't use ourselves.

Founded in 2019, Grannus Therapeutics is a pre-clinical stage biotechnology company, focused on the development of small molecule inhibitors for specific isoforms of HSP90. Our lead program is focused on the development of a highly selective small molecule inhibitor of HSP90𝛽 for the treatment of multiple types of cancer. With this program, we have successfully engineered a molecule that selectively inhibits HSP90𝛽, potentially delivering the efficacy benefits of previous pan-inhibitors without their toxicity and dosing challenges.

The Fūrinkazan Venture Company LLC, is a global entrepreneurial finance & startup advisory company that empowers under-estimated founders who want to start or scale their companies by providing them with the tools & resources to understand and navigate the entrepreneurial ecosystem, and thus be better prepared to close on their next pitch to venture studios, angel investors, and venture capital firms. We also work with universities to develop and enhance their own entrepreneurial ecosystems in order to successfully commercialize their technologies into venture-backed companies. Our vision is to close the gap. In the USA alone, less than 2% of venture capital funding goes to under-estimated founders. This includes but is not limited to: female, Latin, Black, Asian, veterans, and immigrant founders. Our goal is to close the knowledge and access gap for under-estimated founders to achieve their dream of starting their own company, be catalysts of positive change, build wealth, and ultimately transform their communities and the world.

A medical device company that manufactures The TayCo Brace, a custom fit external ankle brace. The TayCo Brace offers immediate functional recovery for driving, work, and sports. It is custom fit for enhanced stability, performance, and comfort. The brace was developed by Mike Bean, the athletic trainer for the University of Notre Dame Football Team. It is rugged enough to withstand the punishment of a NFL or NCAA football game, yet light weight and nimble enough to reduced the risks of additional injuries through the elimination of limb imbalance and avoidance of soft tissue problems associated with casts, walking boots, and AFOs.

Our mission is to provide an easy weight management solution with no negative side effects while building a great team and providing shareholder value. We place focus on being thorough, trustworthy, and data driven. We value fun and are committed to learning and sharing our knowledge. We promise not to sell a product that we wouldn't use ourselves.

Founded in 2019, Grannus Therapeutics is a pre-clinical stage biotechnology company, focused on the development of small molecule inhibitors for specific isoforms of HSP90. Our lead program is focused on the development of a highly selective small molecule inhibitor of HSP90𝛽 for the treatment of multiple types of cancer. With this program, we have successfully engineered a molecule that selectively inhibits HSP90𝛽, potentially delivering the efficacy benefits of previous pan-inhibitors without their toxicity and dosing challenges.